Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 210

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues

Open access
Wolin, Edward, Jarzab, Barbara, Eriksson, Barbro, Walter, Thomas, Toumpanakis, Christos, Morse, Michael A., Tomassetti, Paola, Weber, Matthias M., Fogelman, David, Ramage, John, Poon, Donald, Gadbaw, Brian, Li, Jiang, Pasieka, Janice L., Mahamat, Abakar, Swahn, Fredrik, Newell-Price, John, Mansoor, Wasat, Öberg, Kjell·2015·Drug Design, Development and Therapy

Abstract

In a randomized, double-blind, Phase III study, we compared pasireotide long-acting release (pasireotide LAR) with octreotide long-acting repeatable (octreotide LAR) in managing carcinoid symptoms refractory to first-generation somatostatin analogues. Adults with carcinoid tumors of the digestive tract were randomly assigned (1:1) to receive pasireotide LAR (60 mg) or octreotide LAR (40 mg) every 28 days. Primary outcome was symptom control based on frequency of bowel movements and flushing episodes. Objective tumor response was a secondary outcome. Progression-free survival (PFS) was calculated in a post hoc analysis. Adverse events were recorded. At the time of a planned interim analysis, the data monitoring committee recommended halting the study because of a low predictive probability of showing superiority of pasireotide over octreotide for symptom control (n=43 pasireotide LAR, 20.9%; n=45 octreotide LAR, 26.7%; odds ratio, 0.73; 95% confidence interval [CI], 0.27-1.97; P=0.53). Tumor control rate at month 6 was 62.7% with pasireotide and 46.2% with octreotide (odds ratio, 1.96; 95% CI, 0.89-4.32; P=0.09). Median (95% CI) PFS was 11.8 months (11.0 - not reached) with pasireotide versus 6.8 months (5.6 - not reached) with octreotide (hazard ratio, 0.46; 95% CI, 0.20-0.98; P=0.045). The most frequent drug-related adverse events (pasireotide vs octreotide) included hyperglycemia (28.3% vs 5.3%), fatigue (11.3% vs 3.5%), and nausea (9.4% vs 0%). We conclude that, among patients with carcinoid symptoms refractory to available somatostatin analogues, similar proportions of patients receiving pasireotide LAR or octreotide LAR achieved symptom control at month 6. Pasireotide LAR showed a trend toward higher tumor control rate at month 6, although it was statistically not significant, and was associated with a longer PFS than octreotide LAR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/dddt.s84177

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 210

Metadata

Authors
Wolin, E., Jarzab, B., Eriksson, B., Walter, T., Toumpanakis, C., Morse, M. A., Tomassetti, P., Weber, M. M., Fogelman, D., Ramage, J., Poon, D., Gadbaw, B., Li, J., Pasieka, J. L., Mahamat, A., Swahn, F., Newell-Price, J., Mansoor, W., & Öberg, K.
Venue
Drug Design, Development and Therapy
Published
2015-09
Volume
9
Pages
5075
ISSN
1177-8881 (ISSN-L)
OpenAlex
W1891914108
Cited by
210
References
1
FWCI
17.43
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. https://app.cochat.ai/papers/10.2147/dddt.s84177
The paper
Wolin, E., Jarzab, B., Eriksson, B., Walter, T., Toumpanakis, C., Morse, M. A., Tomassetti, P., Weber, M. M., Fogelman, D., Ramage, J., Poon, D., Gadbaw, B., Li, J., Pasieka, J. L., Mahamat, A., Swahn, F., Newell-Price, J., Mansoor, W., & Öberg, K. (2015). Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s84177

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.